Get to know our clinical trials
Clinical trial to evaluate Iberdomide-dexamethasone alone or in combination with standard multiple myeloma treatment regimens in newly diagnosed patients who are not candidates for transplantation.
THE OBJECTIVE OF THIS STUDY IS TO ASSESS THE EFFICACY OF THE INVESTIGATIONAL DRUG IBERDOMIDE IN COMBINATION WITH DEXAMETHASONE AND ALSO IBERDOMIDE IN COMBINATION WITH DARATUMUMAB (DARZALEX®) AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE NOT CANDIDATES FOR TRANSPLANTATION. THROUGHOUT THE STUDY, THE SAFETY AND TOLERANCE OF THIS DRUG COMBINATION WILL ALSO BE ASSESSED, AS WELL AS THE EVOLUTION IN THE QUALITY OF LIFE OF THE PATIENTS.
Technical Summary
- MULTICENTER, PHASE II, NATIONAL, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE IBERDOMIDE-DEXAMETHASONE ALONE OR IN COMBINATION WITH STANDARD TREATMENT REGIMENS FOR MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS WHO ARE NOT CANDIDATES FOR TRANSPLANTATION.
- Code EudraCT: 2021-002190-25
- Protocol number: GEM-IBERDARAX
- Promoter: Fundación Pethema
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.